Yu Jin, Huang Wei
Department of Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
Int J Stem Cells. 2020 Nov 30;13(3):295-304. doi: 10.15283/ijsc20082.
Breast cancer is the malignant tumor with the highest incidence in women. Nowadays, the objects of models of this disease are mainly from breast cancer cell lines and patient-derived patient-derived xenograft (PDX). However, there is a significant gap between traditional cell lines and breast cancer solid tumors, meanwhiles, PDX is not highly consistent with patients due to different species. As a techonlogy, obtaining patient-derived tumor cells, combined with three-dimensional culture technology, adding cytokines that promotes the proliferation of breast cancer stem cells and inhibit their apoptosis, breast cancer organoids form a structure which is similar to tumor in the body. This model can not only study the occurrence and envolution of breast cancer, but is more prominent in clinical application. screening drugs by high-throughput, personalized treatment, textingtoxicity and immunotherapy. This article will review the breast cancer organoids, in evolution, source, culture system and clinical applications.
乳腺癌是女性中发病率最高的恶性肿瘤。如今,这种疾病模型的对象主要来自乳腺癌细胞系和患者来源的异种移植瘤(PDX)。然而,传统细胞系与乳腺癌实体瘤之间存在显著差距,同时,由于物种不同,PDX与患者的情况并非高度一致。作为一种技术,获取患者来源的肿瘤细胞,结合三维培养技术,添加促进乳腺癌干细胞增殖并抑制其凋亡的细胞因子,乳腺癌类器官形成一种类似于体内肿瘤的结构。该模型不仅可以研究乳腺癌的发生和演变,而且在临床应用中更为突出,可通过高通量筛选药物、个性化治疗、检测毒性和免疫治疗。本文将综述乳腺癌类器官的发展、来源、培养体系及临床应用。